Alteration of plasma total F2-isoprostanes before and after hemodialysis in end-stage renal disease patients

被引:11
作者
Kim, KM
Jung, BH
Paeng, KJ
Kim, SW
Chung, BC
机构
[1] Korea Inst Sci & Technol, Bioanal & Biotransformat Res Ctr, Seoul 130650, South Korea
[2] Yonsei Univ, Dept Chem, Wonju 220710, South Korea
[3] Korea Univ, Anam Hosp Med Coll, Dept Nephrol, Seoul 136705, South Korea
来源
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 2004年 / 70卷 / 05期
关键词
F-isoprostanes; oxidative stress; hemodialysis;
D O I
10.1016/j.plefa.2003.10.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
F-2-isoprostanes are derived in vivo principally from the following: (1) the formation of positional peroxyl radicals of arachidonic acid, (2) endocyclization to prostaglandin G(2)-like structures, and (3) reduction to PGF(2)-like compounds. F-2-isoprostanes have been proposed as biomarkers of lipid peroxidation, oxidative stress status, and the oxidation of low-density lipoprotein (LDL). Using gas chromatography-ion trap-mass spectrometry, we studied how hemodialysis (HD) affects plasma total F-2-isoprostanes. We examined the plasma total F-2-isoprostanes in end-stage renal disease (ESRD) patients, before HD, after HD, between HD, and in control subjects. Plasma concentrations of total F-2-isoprostanes were significantly higher in the after HD ESRD patients than the before hemodialysis ESRD patients (P<0.05). There is no difference between before HD ESRD patients and normal controls. Moreover, a positive or negative correlation was seen between LDL and plasma total F-2-isoprostanes (P<0.001), and between age and plasma total F-2-isoprostanes (P<0.001). This study indicates HD treatment may be the major contributor of oxidative stress in ESRD patients. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:475 / 478
页数:4
相关论文
共 21 条
[1]  
Becker BN, 1997, J AM SOC NEPHROL, V8, P475
[2]   Increased malondialdehyde in peripheral blood of patients with congestive heart failure [J].
DiazVelez, CR ;
GarciaCastineiras, S ;
MendozaRamos, E ;
HernandezLopez, E .
AMERICAN HEART JOURNAL, 1996, 131 (01) :146-152
[3]   Effect of hemodialysis on the oxidative stress and antioxidants [J].
Dursun, E ;
Ozben, T ;
Süleymanlar, G ;
Dursun, B ;
Yakupoglu, G .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (10) :1009-1013
[4]   Lipid peroxidation and antioxidant status in experimental diabetes [J].
Feillet-Coudray, C ;
Rock, E ;
Coudray, C ;
Grzelkowska, K ;
Azais-Braesco, V ;
Dardevet, D ;
Mazur, A .
CLINICA CHIMICA ACTA, 1999, 284 (01) :31-43
[5]   FORMATION OF PGF(2)-ISOPROSTANES DURING THE OXIDATIVE MODIFICATION OF LOW-DENSITY-LIPOPROTEIN [J].
GOPAUL, NK ;
NOUROOZZADEH, J ;
MALLET, AI ;
ANGGARD, EE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 200 (01) :338-343
[6]   Effect of the dialysis membrane on mortality of chronic hemodialysis patients [J].
Hakim, RM ;
Held, PJ ;
Stannard, DC ;
Wolfe, RA ;
Port, FK ;
Daugirdas, JT ;
Agodoa, L .
KIDNEY INTERNATIONAL, 1996, 50 (02) :566-570
[7]  
HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1
[8]   Elevated plasma F2-isoprostanes in patients on long-term hemodialysis [J].
Handelman, GJ ;
Walter, MF ;
Adhikarla, R ;
Gross, J ;
Dallal, GE ;
Levin, NW ;
Blumberg, JB .
KIDNEY INTERNATIONAL, 2001, 59 (05) :1960-1966
[9]   THE AGING PROCESS [J].
HARMAN, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (11) :7124-7128
[10]   Plasma protein thiol oxidation and carbonyl formation in chronic renal failure [J].
Himmelfarb, J ;
McMonagle, E ;
McMenamin, E .
KIDNEY INTERNATIONAL, 2000, 58 (06) :2571-2578